Filing Flows › GeneDx Holdings (WGS) › Q1 2026
GeneDx Holdings (WGS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 4, 2026
GeneDx Holdings (WGS) reported revenue of $102M for the first quarter 2026 (Q1 2026), +17% from a year earlier and -15% from the quarter before. Operating margin was -56.2%, net loss $63.3M (61.9% of revenue).
GeneDx Holdings, Q1 2026: revenue $102M (+17% year over year), operating margin -56.2%, net loss $63.3M, operating cash flow −$32.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $102M | -15% | +17% |
| Operating profit | −$57.5M | — | — |
| Net earnings | −$63.3M | — | — |
| Operating cash flow | −$32.4M | — | -418% |
What changed
Revenue was $102.3M in Q1 2026, up 17% year over year and down 15% from the previous quarter. Patients with third-party insurance was the largest line at 83% of revenue. Patients with third-party insurance added $16.9M year over year (up 25%), 111% of the total change. Other revenue declined 30%.
Gross margin was 66.7%, down 0.4 points from Q1 2025. Operating costs exceeded revenue by $57.5M, an operating margin of -56.2%. Operating expenses grew 99% against revenue growth of 17%. The fastest-growing cost line was Research & development (+57%). The quarter ended with a net loss of $63.3M, wider than the previous quarter's $17.7M loss.
Operating cash flow was −$32.4M. Non-cash charges added back $6.8M of depreciation and amortization and $9.0M of share-based compensation. Working capital and other items added $15.1M. Capital expenditures of $6.5M exceeded it, leaving free cash flow of −$38.9M.
Questions
What was GeneDx Holdings' revenue in the first quarter 2026?
GeneDx Holdings (WGS) reported revenue of $102M for the first quarter 2026 (Q1 2026), +17% from a year earlier and -15% from the quarter before.
Was GeneDx Holdings profitable in the first quarter 2026?
Operating loss was $57.5M (-56.2% of revenue) and net loss $63.3M.
Source: GeneDx Holdings 10-Q on SEC EDGAR.